Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Uner the collaboration, Merck will leverage BenevolentAI’s end-to-end AI platform capabilities to deliver novel drug candidates, initially for three targets in oncology, neurology and immunology. BenevolentAI will identify innovative compounds through Hit Identification to pre-clinical stage.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: $594.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration September 20, 2023
Details:
BEN-8744 is a peripherally restricted small molecule and derived from the Benevolent PlatformTM and is a potential first-in-class PDE10 inhibitor for the treatment of Ulcerative Colitis.
Lead Product(s): BEN-8744
Therapeutic Area: Gastroenterology Product Name: BEN-8744
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2023
Details:
BEN-34712 is an oral, potent and selective brain penetrant RARɑβ (retinoic acid receptor alpha beta) biased agonist and will now enter investigational new drug (IND)-enabling studies for amyotrophic lateral sclerosis.
Lead Product(s): BEN-34712
Therapeutic Area: Neurology Product Name: BEN-34712
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Sheffield Institute for Translational Neuroscience
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2023
Details:
BEN-2293 is a selective inhibitor of the three tropomyosin-related kinases (Trk) receptors (TrkA, TrkB and TrkC) formulated to be administered topically in patients with mild-to-moderate AD.
Lead Product(s): BEN2293
Therapeutic Area: Dermatology Product Name: BEN2293
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2023
Details:
BEN-8744 is an orally administered, peripherally restricted small molecule PDE10 inhibitor under development as a first-in-class treatment for ulcerative colitis and with the potential for other indications within inflammatory bowel disease.
Lead Product(s): BEN-8744
Therapeutic Area: Gastroenterology Product Name: BEN-8744
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
This is the third novel target from the collaboration that has been identified using the Benevolent Platform™ across two disease areas, IPF and chronic kidney disease, and subsequently validated and selected for portfolio entry by AstraZeneca.
Lead Product(s): Undisclosed
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 17, 2022
Details:
The innovative collaboration structure scientists and technologists from the two companies working side-by-side, combining the Benevolent Platform™ — an AI-driven drug discovery platform and biomedical knowledge graph with AstraZeneca’s scientific expertise and rich datasets.
Lead Product(s): Undisclosed
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 15, 2021
Details:
BEN-2293 is a selective Pan-Trk antagonist formulated for topical delivery, with a pharmacokinetic profile designed for low systemic exposure to deliver the optimal safety and efficacy profile in the treatment of itch and inflammation associated with Atopic Dermatitis.
Lead Product(s): BEN-2293
Therapeutic Area: Dermatology Product Name: BEN-2293
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 11, 2021
Details:
AI-generated target was identified through Benevolent Platform® and AstraZeneca's scientific expertise and rich datasets. The Benevolent Platform® predicted this novel target, which was subsequently biologically validated through AstraZeneca's rigorous experimental testing.
Lead Product(s): Undisclosed
Therapeutic Area: Nephrology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 27, 2021
Details:
The randomised control trial included more than 1,000 patients and began on May 8 to assess the efficacy and safety of baricitinib plus remdesivir versus remdesivir in hospitalised patients with COVID-19.
Lead Product(s): Baricitinib
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020